^
    20d
    KEYNOTE-C14: Olinvacimab With Pembrolizumab in Patients With mTNBC (clinicaltrials.gov)
    P2, N=19, Terminated, PharmAbcine | N=30 --> 19 | Recruiting --> Terminated; Subject recruitment issues and follow-up study plans
    Enrollment change • Trial termination
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
    |
    HER-2 negative • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • olinvacimab (TTAC-0001)
    over3years
    TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab (clinicaltrials.gov)
    P2, N=19, Terminated, PharmAbcine | N=36 --> 19 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Jul 2022; Subject recruitment issues and follow-up study plans
    Enrollment change • Trial termination • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    Avastin (bevacizumab) • olinvacimab (TTAC-0001)
    over3years
    TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P1b, N=11, Active, not recruiting, PharmAbcine | Trial completion date: Feb 2022 --> Oct 2022
    Trial completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • olinvacimab (TTAC-0001)
    almost4years
    Olinvacimab With Pembrolizumab in Patients With mTNBC (clinicaltrials.gov)
    P2, N=36, Recruiting, PharmAbcine | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CD4 (CD4 Molecule)
    |
    HER-2 negative • PGR expression
    |
    Keytruda (pembrolizumab) • olinvacimab (TTAC-0001)
    over4years
    TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab (clinicaltrials.gov)
    P2, N=36, Recruiting, PharmAbcine | Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    Avastin (bevacizumab) • olinvacimab (TTAC-0001)
    over4years
    Olinvacimab With Pembrolizumab in Patients With mTNBC (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, PharmAbcine
    Clinical • New P2 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CD4 (CD4 Molecule)
    |
    HER-2 negative • PGR expression
    |
    Keytruda (pembrolizumab) • olinvacimab (TTAC-0001)
    almost5years
    TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P1b, N=11, Active, not recruiting, PharmAbcine | Trial completion date: Apr 2020 --> Feb 2022
    Clinical • Trial completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • olinvacimab (TTAC-0001)
    5years
    [VIRTUAL] A 3-Arm, Phase IIa Trial of Safety & Efficacy of Olinvacimab, a Monoclonal Antibody to VEGFR2 in Patients with Recurrent Glioblastoma Multiforme with Imaging and PK/PD assessments: Final report (SNO 2020)
    Eligible patients were ≥18 years with RANO-measurable lesion, KPS ≥ 80, and had completed chemoradiotherapy without prior bevacizumab therapy. Olinvacimab was well tolerated with a different toxicity profile to other VEGFR directed therapies. There were promising responses in 25% of patients.
    Clinical • P2a data • PK/PD data
    |
    KDR (Kinase insert domain receptor)
    |
    VEGFA elevation
    |
    Avastin (bevacizumab) • olinvacimab (TTAC-0001)
    over5years
    [VIRTUAL] Phase Ib study of olinvacimab (O) with pembrolizumab (P) in patients with recurrent glioblastoma (rGBM). (ASCO 2020)
    Eligible patients (pts) were ≥18 years with at least one RANO-measurable lesion, KPS≥80, and had completed standard chemoradiotherapy and had no contraindications to O or P. No prior bevacizumab was allowed. The combination of O with P was safe and tolerable at the full single agent dose of each drug. No DLTs were observed. The combination did not show efficacy in this setting.
    Clinical • P1 data
    |
    KDR (Kinase insert domain receptor)
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • olinvacimab (TTAC-0001)
    almost6years
    TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P1b, N=11, Active, not recruiting, PharmAbcine | Recruiting --> Active, not recruiting | N=20 --> 11
    Clinical • Enrollment closed • Enrollment change • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • olinvacimab (TTAC-0001)